Company intelligence / Profile preview

Amega Biotech

Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentinaamegabiotech.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Amega Biotech is a leading Latin American developer and manufacturer of biosimilars and recombinant proteins. The company has a portfolio of at least fifteen active pharmaceutical ingredients covering major biologic classes such as growth factors, hormones, cytokines/interferons, and monoclonal antibody fragments. Its products are commercialized in more than twenty countries worldwide. Clinical data are not detailed publicly but the company’s products are registered in central markets indicating successful regulatory approvals for their biosimilars.

Therapeutic areas: Infectious DiseasesOncologyEndocrinologyImmunologyHematologyWomen's Health
Modalities: Recombinant proteinBiologicBiosimilar
Industry: Biotech

Drug pipeline

4 assets

Suprimun

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Amega Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amega Biotech.